Global Bipolar Disorder Drugs and Treatment Industry Anticipated to Grow at 2.72% CAGR, Reaching US$ 5.8 Billion by 2033 | FMI analysis

Global Bipolar Disorder Drugs and Treatment Industry

The Global Industry For Bipolar Disorder Drugs And Treatment is on a trajectory of stable expansion, with a projected Compound Annual Growth Rate (CAGR) of 2.72% from the end of 2023 to the year 2033. This growth is anticipated to propel the market valuation from US$ 4.4 Billion to a remarkable US$ 5.8 Billion, as revealed by a recent study conducted by Future Market Insights.

According to the study, anti-psychotic drugs are at the forefront of driving this growth, expected to capture a substantial market share of about 40.2% by the year 2023 on a global scale. Future Market Insights’ historical analysis indicates a consistent expansion in the Global Bipolar Disorder Drugs and Treatment Industry , registering a CAGR of 2.10% from 2017 to 2022.

Claim your complimentary report with captivating visuals.
https://www.futuremarketinsights.com/reports/sample/rep-gb-14407

A significant rise has been witnessed in the demand for natural bipolar meds or drugs is anticipated to grow by the patients suffering from such disease. A similar category of drugs, commonly known as bipolar depression treatment medication, is increasingly available in all parts of the world. The healthcare sector was kept as one of the most vital business sectors globally. Some remarkable developments have been witnessed in the field of herbal medicine for bipolar disorder which has emerged as a successful niche for the bipolar disorder drugs and treatment market.

Key Takeaways:

• Bipolar disorders have been recognized as the 6^th largest contributor to the total disabled person throughout the world, revealed by World Health Organization. To mitigate the serious consequences, modern medical science has developed therapeutic drugs for its treatment that are available as over-the-counter meds in drug stores.
• Previously, the consciousness and awareness concerning the remedial measures for any type of mental disorder were considered below the level. This has resulted in less demand for good medicine for bipolar disorder produced by pharmaceutical companies. However, in the recent past, the surging digital media impact and the acceptance of methods for the treatment of bipolar is reflected in the huge growth in sales of over-the-counter meds for bipolar cases.
• Some old-age natural medication used for bipolar disorder that is actively being researched and developed by pharmaceutical companies to augment their customer base. Many market players have succeeded in creating brand value by supplying mood stabilizers online to customers.
• The demand for medication concerning bipolar disorder from hospitals and healthcare institutes dropped significantly. Surprisingly enough, the number of patients diagnosed with bipolar disorders increased significantly during the worldwide shutdown. However, the market growth for prescribed drugs continued through the increase in the online availability of bipolar meds on e-commerce sites.

Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14407

Competitive Landscape:

The major strategies adopted by key players within the global bipolar disorder drugs and treatment market include the development of new drugs for bipolar disorder counter medication by investing in research and development (R&D) activities. Acquiring approvals for such over-the-counter medications is the most important step in gaining recognition for newly developed medicines. Furthermore, expanding business activities by acquisition and merger of the locally established manufacturers supplying mood stabilizer medications over the counter in any area.

More Insights into the Global Bipolar Disorder Drugs and Treatment Industry :

The North American region is anticipated to dominate the Global Bipolar Disorder Drugs and Treatment Industry. The United States is set to account for around 52.90% of the total market share in 2023.

According to the National Institute of Mental Health (NIMH) data, it has been estimated that the number of people in the USA developing bipolar disorder symptoms at approximately 10 million. With the support of government initiatives and the dissemination of knowledge about the mental condition of such patients, there has been an encouraging environment for their treatment through proper medication for bipolar disorder.

Germany is expected to bode well for the Global Bipolar Disorder Drugs and Treatment Industry by accounting for around 6.90% in 2023.

Top 12 Key Companies Profiled:

1. AbbVie Inc.
2. Glaxo SmithKline (GSK)
3. ELI Lilly and Company
4. Janssen Pharmaceuticals
5. Astellas Pharma Inc.
6. Bristol Myers Squibb
7. Gedeon Richter Plc.
8. Lundbeck A/S
9. Pfizer Inc.
10. Novartis AG
11. Otsuka Holdings Co. Ltd
12. Validus Pharmaceuticals LLC

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/14407

Key Market Segments Covered in Global Bipolar Disorder Drugs and Treatment Industry Research

Drug Class:

• Mood Stabilizer
• Anticonvulsants
• Anti-Psychotic Drugs
• Anti-Depressant Drugs
• Anti-Anxiety Drugs

Bipolar Disorder:

• Bipolar I Disorder
• Bipolar Ii Disorder
• Cyclothymic Disorder

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube